All In Biotech

Drug Trial Radar · NCT07305974

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic/Pharmacodynamic Characteristics of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 8, 2025

Primary completion

Mar 31, 2029

Study completion Mar 31, 2029

Sponsor

Sponsor type
Industry
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is being given.

Conditions

  • IgA Nephropathy (IgAN)

Interventions

  • RG002C0106Drug

    RG002C0106 for subcutaneous (SC) injection

  • placebo subcutaneous administrationDrug

    The placebo is made of normal saline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage change from baseline in the mean 24hUPCR)at Week 24 after the first subcutaneous admini;Time frame: up to 169 days
  2. Incidence of adverse events (AEs) and serious adverse events (SAEs) related to the investigational drug.Time frame: up to 169 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.